233 related articles for article (PubMed ID: 31792737)
41. Use of Melatonin in Cancer Treatment: Where Are We?
Wang L; Wang C; Choi WS
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409137
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Antioncogenic Action.
Wu H; Liu J; Yin Y; Zhang D; Xia P; Zhu G
Biomed Res Int; 2019; 2019():9740568. PubMed ID: 31637261
[TBL] [Abstract][Full Text] [Related]
43. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Lissoni P; Tancini G; Paolorossi F; Mandalà M; Ardizzoia A; Malugani F; Giani L; Barni S
J Pineal Res; 1999 Apr; 26(3):169-73. PubMed ID: 10231730
[TBL] [Abstract][Full Text] [Related]
44. Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer.
Eng C
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S53-9. PubMed ID: 18021488
[TBL] [Abstract][Full Text] [Related]
45. New perspectives in melatonin uses.
Carpentieri A; Díaz de Barboza G; Areco V; Peralta López M; Tolosa de Talamoni N
Pharmacol Res; 2012 Apr; 65(4):437-44. PubMed ID: 22311380
[TBL] [Abstract][Full Text] [Related]
46. Emerging drugs in refractory colorectal cancer.
Nobili S; Galletta A; Brugia M; Tassi R; Petreni P; Landini I; Mini E
Future Med Chem; 2015 Aug; 7(12):1491-501. PubMed ID: 26293581
[TBL] [Abstract][Full Text] [Related]
47. Understanding the oncostatic actions displayed by melatonin in colorectal cancer therapy.
Gil-Martín E; López-Muñoz F; Reiter RJ; Romero A
Future Med Chem; 2020 Jul; 12(13):1201-1204. PubMed ID: 32466682
[No Abstract] [Full Text] [Related]
48. Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin.
Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Hemati K; Ghaznavi H; Mehrzadi S
Life Sci; 2018 May; 201():17-29. PubMed ID: 29567077
[TBL] [Abstract][Full Text] [Related]
49. Overview of biological effects of melatonin on testis: A review.
Heidarizadi S; Rashidi Z; Jalili C; Gholami M
Andrologia; 2022 Dec; 54(11):e14597. PubMed ID: 36168927
[TBL] [Abstract][Full Text] [Related]
50. Boosting immune system against cancer by melatonin: A mechanistic viewpoint.
Mortezaee K; Potes Y; Mirtavoos-Mahyari H; Motevaseli E; Shabeeb D; Musa AE; Najafi M; Farhood B
Life Sci; 2019 Dec; 238():116960. PubMed ID: 31629760
[TBL] [Abstract][Full Text] [Related]
51. Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells.
Fragale A; Romagnoli G; Licursi V; Buoncervello M; Del Vecchio G; Giuliani C; Parlato S; Leone C; De Angelis M; Canini I; Toschi E; Belardelli F; Negri R; Capone I; Presutti C; Gabriele L
Cancer Immunol Res; 2017 Jul; 5(7):604-616. PubMed ID: 28615266
[TBL] [Abstract][Full Text] [Related]
52. Emerging drugs for colorectal cancer.
Fogelman DR; Kopetz S; Eng C
Expert Opin Emerg Drugs; 2008 Dec; 13(4):629-42. PubMed ID: 19046131
[TBL] [Abstract][Full Text] [Related]
53. Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.
Maleki Dana P; Reiter RJ; Hallajzadeh J; Asemi Z; Mansournia MA; Yousefi B
IUBMB Life; 2020 Nov; 72(11):2355-2365. PubMed ID: 32918860
[TBL] [Abstract][Full Text] [Related]
54. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
55. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
Lemos C; Sack U; Schmid F; Juneja M; Stein U
Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
[TBL] [Abstract][Full Text] [Related]
56. Melatonin and Hippo Pathway: Is There Existing Cross-Talk?
Lo Sardo F; Muti P; Blandino G; Strano S
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28878191
[TBL] [Abstract][Full Text] [Related]
57. Prospects of the clinical utilization of melatonin.
Bubenik GA; Blask DE; Brown GM; Maestroni GJ; Pang SF; Reiter RJ; Viswanathan M; Zisapel N
Biol Signals Recept; 1998; 7(4):195-219. PubMed ID: 9730580
[TBL] [Abstract][Full Text] [Related]
58. Melatonin in cancer management: progress and promise.
Jung B; Ahmad N
Cancer Res; 2006 Oct; 66(20):9789-93. PubMed ID: 17047036
[TBL] [Abstract][Full Text] [Related]
59. Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
Kim SL; Kim SH; Park YR; Liu YC; Kim EM; Jeong HJ; Kim YN; Seo SY; Kim IH; Lee SO; Lee ST; Kim SW
Mol Cancer Res; 2017 Feb; 15(2):141-151. PubMed ID: 28108625
[TBL] [Abstract][Full Text] [Related]
60. Targeting cancer stem cells as therapeutic approach in the treatment of colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Hassanian SM; Parizadeh SMR; Vojdani S; Ghandehari M; Ghazaghi A; Khazaei M; Shahidsales S; Rezayi M; Asgharzadeh F; Ghayour-Mobarhan M; Ferns GA; Avan A
Int J Biochem Cell Biol; 2019 May; 110():75-83. PubMed ID: 30818083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
